Formulation and evaluation of doxazosin mesylate loaded niosomes for prostate cancer
Dr. Syed Mohammed kazim, Fareeaa Ashar, Arifa Banu, Mukund Panukanti
Cancer is defined as an uncontrolled growth of abnormal (neoplastic) cells. Prostate cancer is the second most commonly occurring cancer in men and the fourth most commonly occurring cancer overall. Use of chemotherapeutic agents is treatment of choice for prostate cancer. Doxazosin Mesylate, an α-1 adrenoreceptor antagonists, have shown anticancer activities against prostate cancer via induced apoptosis. Niosomes are the promising surfactant-based drug carriers, formed mostly by non-ionic surfactant and cholesterol. Formulation of Doxazosin mesylate as niosomes helps in passive targeting of drug delivery. Doxazosin Mesylate loaded niosomes were prepared using thin film hydration method. Different grades of spans and tweens were selected for the preparation of niosomes. The prepared niosomes were evaluated for size, shape, lamellarity, entrapment efficiency and percentage drug release. Fourier-transform infrared spectroscopy of doxazosin mesylate and the excipients has shown no incompatabilities. Scanning electron microscopy of the niosomal formulations (F1-F4) has shown that all the prepared niosomes are spherical in shape with smooth surface and are multilamellar in nature. Entrapment efficiency of the niosomal formulations (F1-F4) were evaluated and F1 has shown the maximum entrapment efficiency of 94.87%. All the prepared niosomal formulations (F1-F4) were evaluated for percentage drug release and F1 formulation has shown the maximum drug release over a time span of 12h. From the above discussion it can be concluded that doxazosin mesylate loaded niosomes can help in treatment of prostate cancer by passive targeting.
Dr. Syed Mohammed kazim, Fareeaa Ashar, Arifa Banu, Mukund Panukanti. Formulation and evaluation of doxazosin mesylate loaded niosomes for prostate cancer. International Journal of Research in Pharmacy and Pharmaceutical Sciences, Volume 4, Issue 5, 2019, Pages 47-50